Barak Ben Arye - 14 Apr 2022 Form 3 Insider Report for NovoCure Ltd (NVCR)

Role
General Counsel
Signature
By: /s/ Steven Robbins, Attorney in Fact for Barak Ben Arye
Issuer symbol
NVCR
Transactions as of
14 Apr 2022
Net transactions value
$0
Form type
3
Filing time
14 Apr 2022, 16:36:36 UTC
Next filing
07 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NVCR Ordinary Shares 4,223 14 Apr 2022 Direct
holding NVCR Restricted Share Units 299 14 Apr 2022 Direct F1
holding NVCR Restricted Share Units 7,605 14 Apr 2022 Direct F2
holding NVCR Restricted Share Units 870 14 Apr 2022 Direct F3
holding NVCR Restricted Share Units 464 14 Apr 2022 Direct F4
holding NVCR Restricted Share Units 2,016 14 Apr 2022 Direct F5
holding NVCR Restricted Share Units 1,381 14 Apr 2022 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 780 $83.30 Direct F7
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 2,851 $21.15 Direct F8
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 7,990 $69.37 Direct F9
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 2,432 $47.04 Direct F10
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 13,131 $87.66 Direct F11
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 831 $107.73 Direct F12
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 3,532 $80.59 Direct F13
holding NVCR Options to Buy Ordinary Shares 14 Apr 2022 Ordinary Shares 2,401 $153.09 Direct F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest on July 30, 2022, subject to the reporting person's continued employment through such dates.
F2 Represents restricted share units that are scheduled to vest on April 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F3 Represents restricted share units that are scheduled to vest on March 2, 2023 and 2024, subject to the reporting person's continued employment through such dates.
F4 Represents restricted share units that are scheduled to vest on November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
F5 Represents restricted share units that are scheduled to vest on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F6 Represents restricted share units that are scheduled to vest on March 3, 2023, subject to the reporting person's continued employment through such dates.
F7 Options to buy 780 ordinary shares will vest in equal installments on each of July 30, 2022 and 2023, subject to the reporting person's continued employment through such dates.
F8 Currently exercisable.
F9 Options to buy 7,990 ordinary shares, 3,996 shares of which are currently exercisable and the remainder vest in equal installments on each of March 3, 2023 and 2024, subject to the reporting person's continued employment through such dates.
F10 Options to buy 2,432 ordinary shares, 1,216 shares of which are currently exercisable and the remainder vest on March 22, 2023, subject to the reporting person's continued employment through such dates.
F11 Options to buy 13,131 ordinary shares will vest in equal installments on each of April 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F12 Options to buy 831 ordinary shares will vest in equal installments on each of November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
F13 Options to buy 3,532 ordinary shares will vest in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F14 Options to buy 2,401 ordinary shares, 601 shares of which are currently exercisable and the remainder vest in equal installments on each of March 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.